SEC Comment Letter 0000000000-23-013402 to BeOne Medicines Ltd. (BEIGF)

BeOne Medicines Ltd.
Date: Dec. 7, 2023 · CIK: 0001651308 · Accession: 0000000000-23-013402

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-37686

Date

December 7, 2023

Author

John V. Oyler

Form

UPLOAD

Company

BeOne Medicines Ltd.

Letter

United States securities and exchange commission logo December 7, 2023 John V. Oyler Chief Executive Officer BeiGene, Ltd. 94 Solaris Avenue, Camana Bay Grand Cayman Cayman Islands KY1-1108 Re:BeiGene, Ltd. Form 10-K for the Fiscal Year Ended December 31, 2022 File No. 001-37686 Dear John V. Oyler: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Disclosure Review Program cc: Edwin M. O'Connor

Show Raw Text

United States securities and exchange commission logo
December 7, 2023
John V. Oyler
Chief Executive Officer
BeiGene, Ltd.
94 Solaris Avenue, Camana Bay
Grand Cayman
Cayman Islands KY1-1108
Re:BeiGene, Ltd.
Form 10-K for the Fiscal Year Ended December 31, 2022
File No. 001-37686
Dear John V. Oyler:
            We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Disclosure Review Program
cc:       Edwin M. O'Connor

SecProbe.io